Prevalence and genotype distribution of hepatitis delta virus among chronic hepatitis B carriers in Central Vietnam

Hung Minh Nguyen1*, Bui Tien Sy2*, Nguyen Thanh Trung1, Nghiem Xuan Hoan3, Heiner Wedemeyer4, Thirumalaisamy P. Velavan1,3,5‡, C-Thomas Bock6‡*

1 Center for Molecular Biology, Institute of Research and Development, Duy Tan University, Da Nang, Vietnam, 2 Department of Molecular Biology, 108 Military Central Hospital, Hanoi, Vietnam, 3 Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany, 4 German Center for Infection Research, Department for Gastroenterology, Hepatology, and Endocrinology, Medical School Hannover, Hannover, Germany, 5 Vietnamese-German Center for Medical Research, Hanoi, Vietnam, 6 Department of Infectious Diseases, Robert Koch Institute, Berlin, Germany

* These authors contributed equally to this work.
‡ These authors share senior authorship on this work
○ bockc@rki.de (CTB); hungmolbio@gmail.com (HMN)

Abstract

Hepatitis D virus (HDV) infection plays an important role in liver diseases. However, the molecular epidemiology and impact of HDV infection in chronic hepatitis B (CHB) remain uncertain in Vietnam. This cross-sectional study aimed to investigate the prevalence and genotype distribution of HDV among HBsAg-positive patients in Central Vietnam. 250 CHB patients were tested for HDV using newly established HDV-specific RT-PCR techniques. HDV genotypes were determined by direct sequencing. Of the 250 patients 25 (10%) had detectable copies of HDV viral RNA. HDV-2 was predominant (20/25; 80%) followed by HDV-1 (5/25; 20%). Proven HDV genotypes share the Asian nomenclature. Chronic hepatitis B patients with concomitant HDV-1 showed higher HBV loads as compared to HDV-2 infected patients [median log10 (HBV-DNA copies/ml): 8.5 vs. 4.4, P = 0.036]. Our findings indicate that HDV infection is highly prevalent and HDV-2 is predominant in Central Vietnam. The data will add new information to the management of HBsAg-positive patients in a highly HBV endemic region to in- or exclude HDV infection in terms of diagnostic and treatment options.

Introduction

Hepatitis D, caused by the hepatitis Delta virus (HDV) is a unique RNA pathogen, which needs hepatitis B virus (HBV) envelope proteins to infect the hepatocytes. HBV-HDV coinfection can accelerate the liver diseases [1–4]. Among 250 million chronic HBsAg carriers worldwide [5], approximately 12.5 million individuals had been coinfected with HDV [6].

HDV is a small single-stranded negative-sense circular RNA virus which encompasses a spherical “HDAg and HBsAg-hybrid” particle of ~36 nm in diameter, and an outer envelope
containing hepatitis B surface antigens (HBsAg) [7, 8]. The HDV genome consists of approx. 1680 nucleotides covered by approximately 200 hepatitis D antigen molecules (HDAg) [2, 9]. HDV needs the presence of HBV envelope proteins for its assembly, propagation, and transmission to initiate new rounds of infection [6, 10]. However, HDV can replicate within non HBV infected hepatocytes since no helper function for HDV RNA synthesis and RNP assembly is required by HBV [10, 11]. The open reading frame of HDV encodes unique delta antigens, the small and the large isoforms of S-HDAg and L-HDAg. The S-HDAg is responsible for HDV replication initiation, whereas the L-HDAg is required for viral packaging [10, 12]. HDV can be acquired either as a coinfection with acute hepatitis B or as a super infection especially in chronically HBV infected individuals [13].

HDV viruses have been separated into at least eight major clades based on their genome diversity, with specific geographic distribution [6, 14]. HDV-1 is the frequently occurring clade and is distributed among Europe, Middle East, America and North Africa [15–18]. HDV-2 to HDV-8 occur regionally [19]. For instance, HDV-2 prevails in countries like Japan [20], Taiwan [21, 22] and Russia [23]. HDV-3 which is a most diverged genotype is exclusively found in South America [18, 24, 25]. HDV-4 is reported across Japan and Taiwan [21]; whereas HDV-5 to HDV-8 are described in Africa [26, 27].

The distribution of HDV varies with different geographical regions with a higher incidence in Middle East, Mediterranean, Amazonas, African, and in Asian countries [6, 14, 28]. Vietnam is a South-East Asian country with a high prevalence of HBV infection and approximately 10–20% of general populations live with chronic hepatitis B [29, 30]. High prevalence of HDV is reported in HBsAg positive patients in Northern provinces of Vietnam, especially in patients with acute hepatitis B with up to 43% [31]. The previous study reported that 15% of HBV patients were positive for HDV-RNA and HDV-2 is predominant in this specific region [31]. In contrast, another studies conducted in two rural districts from Northern Vietnam reported a low HDV prevalence (1%) in HBsAg positive individuals [32]. Although studies have shown considerable proportion of HDV-HBV coinfection in Northern provinces, no studies exist till date on the prevalence of HDV-HBV coinfection in Central and South provinces of Vietnam. Therefore, this study aimed to investigate the prevalence and genotype distribution of HDV in HBsAg-positive patients in Central Vietnam. Furthermore, HDV genotypes were correlated with clinical aspects in HBV-HDV coinfected patients.

Materials and methods

Study subjects

A total of 250 chronic hepatitis B patients were recruited for this cross-sectional study from March to June 2015. The study subjects visited for blood checking or admitted for the treatment in the Hoan My hospital, Da Nang, Vietnam. These patients were from three South Central provinces, namely Da Nang, Quang Nam, and Quang Ngai provinces.

The inclusion criteria were HBV patients positive for HBsAg and negative for anti-HCV and anti-HIV antibodies as determined by ELISA assays (Diagnostic automation/Cortez Diagnostics, Inc., Woodland Hills, California, USA). Patients with other relevant liver diseases such as autoimmune hepatitis, alcoholic or toxic liver disease, and hemochromatosis were excluded from the study. All HBV patients were treatment naive. All patients did not present cirrhosis and/or liver cancer. The clinical parameters were collected, including ALT, AST, total bilirubin, direct bilirubin. Five ml of venous blood were collected from all participants at the time of visit or admission. Serum or plasma was separated from blood and used for biochemical and other laboratory routine procedures. Samples were stored at -80˚C until further use.
Ethics statement

Informed written consent was obtained after detailed explanation of the study at the time of sampling from all participants or from their parents if subjects were less than 18 years. The study was approved by the institutional review board of the Hoan My Hospital, Da Nang, Vietnam and from Duy Tan University, Da Nang, Vietnam.

Viral nucleic acid extraction and cDNA synthesis

Nucleic acid (DNA and RNA) were extracted from 200 μL sera using High Pure Viral Nucleic Acid kit (Roche Diagnostics GmbH, Mannheim, Germany) following the manufacturer’s instruction and stored until use in aliquots at -80˚C. Synthesis of cDNA was performed using First Strand cDNA Synthesis Kit for RT-PCR (Roche GmbH, Mannheim, Germany) following the manufacturer’s instructions.

Molecular detection and genotyping of HDV

HDV-specific nested PCRs were performed with reverse transcribed cDNA samples as template using four highly conserved primer pairs representing all eight HDV genotypes as previously described [31]. HDV nomenclature was according recent reports [26, 33]. The first round of the PCR amplification was performed with 100 ng of cDNA using the FastStart PCR Master Kit (Roche Diagnostics GmbH, Mannheim, Germany) and primer pairs HDV57-F and HDV60-R (nucleotide 299 to 770 as referred to NC001653). The amplicons from first round were used as templates for the subsequent second PCR using primer pairs HDV48-F and HDV54-R targeting specific regions in the HDV genome. The details of primer pairs employed and specific regions along with necessary conditions are described in Table 1.

In order to determine HDV genotypes the L-HDAg (nucleotides 888 to 1122 as referred to NC001653) regions were amplified as previously described [31]. Nested PCRs were performed using primer pairs HDV04-F and HDV05-R for first PCR and primer pairs HDV06-F and HDV07-R for second PCR (Table 1). PCR reactions were performed at 95˚C for 2 min followed by 95˚C for 30 sec, 54˚C for 45 sec, and 72˚C for 45 sec for 35 cycles, with a final extension for 10 min at 72˚C. The amplicons were visualized on 1.5% agarose gels. In addition, the results were verified and validated in another, independent laboratory at 108 Military Central

Table 1. Primers used for HDV detection.

<table>
<thead>
<tr>
<th>Primers</th>
<th>Sequence (5’- 3’)</th>
<th>Position</th>
<th>PCR round</th>
<th>Refs</th>
</tr>
</thead>
<tbody>
<tr>
<td>HDV04-F</td>
<td>GAGATGCCAGTGGAGCCGG</td>
<td>856–874</td>
<td>1st round PCR</td>
<td>[31]</td>
</tr>
<tr>
<td>HDV05-R</td>
<td>AAGAAAGAAGCGGCCGCGG</td>
<td>1159–1179</td>
<td>1st round PCR</td>
<td></td>
</tr>
<tr>
<td>HDV06-F</td>
<td>ATGCCATGCCGACCCGAAGA</td>
<td>888–907</td>
<td>2nd round PCR</td>
<td></td>
</tr>
<tr>
<td>HDV07-R</td>
<td>GGGAGCGGCCGCGGCGGG</td>
<td>1104–1122</td>
<td>2nd round PCR</td>
<td></td>
</tr>
<tr>
<td>HDV57-F</td>
<td>GAGAAAGACACCTCCAGAGGA</td>
<td>299–318</td>
<td>1st round PCR</td>
<td>[34]</td>
</tr>
<tr>
<td>HDV60-R</td>
<td>TCCCATTGCCATTACGGA</td>
<td>752–770</td>
<td>1st round PCR</td>
<td></td>
</tr>
<tr>
<td>HDV48-F</td>
<td>AGAGACCCCTTTACGGAAAC</td>
<td>313–332</td>
<td>2nd round PCR</td>
<td></td>
</tr>
<tr>
<td>HDV54-R</td>
<td>CCGGATTAGCCTTACCTCG</td>
<td>467–485</td>
<td>2nd round PCR</td>
<td></td>
</tr>
<tr>
<td>HBV22-F</td>
<td>TGCTGCTATGGCCATCTTTC</td>
<td>414–433</td>
<td>1st round PCR</td>
<td>[35]</td>
</tr>
<tr>
<td>HBV65-R</td>
<td>CAACGACCAAAAGAATTGG</td>
<td>822–803</td>
<td>1st round PCR</td>
<td></td>
</tr>
<tr>
<td>HBV66-R</td>
<td>CACAGATACACAAAAATTGG</td>
<td>822–803</td>
<td>1st round PCR</td>
<td></td>
</tr>
<tr>
<td>HBV24-F</td>
<td>CAAGCTATGTTGCCGTTGTGAC</td>
<td>455–478</td>
<td>2nd round PCR</td>
<td></td>
</tr>
<tr>
<td>HBV41-R</td>
<td>GGCTCAGATGGTGGTACAG</td>
<td>786–767</td>
<td>2nd round PCR</td>
<td></td>
</tr>
<tr>
<td>HBV64-R</td>
<td>GGGACAGATGGTGGCACAG</td>
<td>786–767</td>
<td>2nd round PCR</td>
<td></td>
</tr>
</tbody>
</table>

https://doi.org/10.1371/journal.pone.0175304.t001
hospital and reference Centre in Hanoi, Vietnam, which is certified for hepatitis molecular diagnostics. The PCR amplicons were subsequently used for sequencing to determine patient-specific HDV isolates.

**Quantification of HBV and HBV genotyping**

Total viral nucleic acids extracted from 200 μL sera were used for HBV quantification and genotyping. HBV quantification was performed using HBV Real-TM Quant Dx (Sacace Biotechnologies, Como, Italy) following the manufacturer’s instructions. HBV genotyping was performed using nested PCR as described [36]. The first round of HBV-specific nested PCR was performed with 2.0 μL total viral nucleic acids (about 400 ng) using FastStart PCR Master Kit (Roche Diagnostics GmbH, Mannheim, Germany), with three primers (HBV22-F, HBV66-R, and HBV65-R) as described in Table 1. The amplicons from first round were used as templates for the second PCR using three nested primers (HBV24-F, HBV64-R, and HBV41-R) as described in Table 1. Initial denaturation was at 95˚C for 2 min. The PCR thermal conditions were performed as first round (95˚C for 30 sec, 55˚C for 30 sec, and 72˚C for 30 sec for 35 cycles) and second round (95˚C for 30 sec, 50˚C for 30 sec, and 72˚C for 30 sec for 30 cycles) followed by a final extension for 10 min at 72˚C for both PCR rounds. The amplicons were visualized on 1.5% agarose-gels and were subsequently used for sequencing to determine patient-specific HBV genotypes.

**Sequencing and phylogenetic analyses**

In order to determine patient-specific HDV isolates, PCR products were gel-eluted using the Gene JET Gel Extraction Kit (ThermoScientific, Lithuania) following the manufacturer’s instructions. 5 μL of eluted PCR amplicons was subjected to cycle sequencing with 1.0 μL of the ABI Prism BigDye terminator cycle sequencing ready reaction kit (Applied Biosystems Inc., Foster city, California, USA) using 0.5 μL of each inner sense and inner antisense primers (HDV48-F/ HDV54-R, and HDV06-F/HDV07-R) on a ABI 3500 Automated Genetic Analyser (Applied Biosystems Inc., Foster city, California, USA). Consensus sequences were generated by alignment of both sequenced strands with forward/sense and reverse/antisense primers after validation using BioEdit 9.7 and DNAstar software V7. The phylogenetic tree was reconstructed from nucleotide sequences using the MEGA 7 software [37]. The phylogenetic tree was reconstructed using the Neighbor-Joining tree methodology that utilizes maximum likelihood approach.

For alignment and HDV genotyping, eight prototype HDV-sequences retrieved from the NCBI GenBank were used (HDV-1: AF098261, AJ000558, AY633627, HM046802, NC001653, KF660660, KF660661, KF660662; HDV-2: KF660599, AF104264, AF425645, AY261457, AY261459, AF261460; HDV-3: AB037947, AB037948, AB037949; HDV-4: AF018077, AF209859; HDV-5: AM183326, AM183331, JA417551; HDV-6: AM183332; HDV-7: AM183333, AM183337, JA417541; HDV-8: AM183327, AM183330).

For alignment and HBV-genotyping, seven HBV-genotype sequences retrieved from the NCBI GenBank were used (HBV genotype A: Z72478, KU605532; HBV genotype B: D00330, AB033554; HBV genotype C: AY040627, X52939; HBV genotype D: KT235604, AY233296; HBV genotype E: X75657, AB032431; HBV genotype F: AB036920, AB036910; HBV genotype G: AB056515, AF405706).

**Statistical analysis**

Statistical analysis was performed by using R software (http://www.r-project.org). Categorical data were compared by Fisher’s exact test. Non-parametric data were compared by using the Mann-Whitney U test, with a 2-tailed p-value <0.05 considered to be statistically significant.
Results

Baseline characteristics of the HBsAg-positive patients

This cross-sectional study was performed on 250 chronic HBsAg-positive patients in South Central Vietnam. Of the investigated study subjects, 169/250 (68%) were male and 81/250 (32%) were female individuals. The median age of the patients was 36 (11–76 years). The median HBV loads were 4.4 [2.4–9.2 (log10 HBV-DNA)]. The median of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) levels, and total and direct bilirubin concentrations were 27 IU/L (10–591), 24 IU/L (9–974), 7.8 μmol/L (2.2–59.1), 3.0 μmol/L (0.3–40.5), respectively (Table 2).

HDV infection in chronic hepatitis B patients

In order to diagnose a HDV infection in chronic HBsAg-positive patients, a recently described sensitive and specific-HDV nested PCR methodology was employed (Fig 1). Alignment of the nested HDV primer sequences showed that the sequences are highly conserved between different HDV-strains and HDV-genotypes of different geographic areas (Fig 1). The HDV nested PCR amplifies a region in the HDV genome which is localized between nucleotides (nt) 313 to nt 485 (numbering is referred to NC001653) that yields an amplicon size of 172 bp (Fig 1).

HDV-RNA was detected in 25/250 (10%) chronic HBsAg-positive patients. Of the 25 HDV positive patients, 15/25 were male (60%) and 10/25 were female (40%). The median age of the HDV-HBV coinfected patients was 38 (22–62 years), and there was no significant difference between males 35 (24–50 years) and females 41.5 (22–62 years) (Table 2).

Association with HDV infection and HBV genotypes

In order to determine the distribution of HBV genotypes in HDV positive patients, the HDV-HBV coinfected samples were further selected for HBV genotypes. HBV-genotyping showed that HBV-genotypes B (22/25; 88%) and C (3/25; 12%) were predominant (Table 3 and Fig 2). Other HBV genotypes were not detected in this study population. We also compared HBV loads between HBV genotypes within HDV positive samples. HBV loads were not significantly distributed between HBV genotypes (HBV-genotype B vs. C: 5.14 ± 2.29 log10 copies/mL vs. 6.37 ± 1.96 log10 copies/mL; P = 0.39) (data not shown).

HDV and chronic HBV infection clinical outcomes

The clinical and subclinical characteristics of the patients with or without HDV infection were presented in Table 2 and Fig 3. The mean age did not differ between two groups (P = 0.52).

Table 2. Baseline data and clinical characteristics of the HBV patients.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>HBV positive (n = 250)</th>
<th>HDV negative (n = 225)</th>
<th>HDV positive (n = 25)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>36 (11–76)</td>
<td>36 (11–76)</td>
<td>38 (22–62)</td>
</tr>
<tr>
<td>Gender (male/female)</td>
<td>169/81</td>
<td>154/71</td>
<td>15/10</td>
</tr>
<tr>
<td>ALT (IU/L)</td>
<td>27 (10–591)</td>
<td>28 (10–591)</td>
<td>22 (10–253)</td>
</tr>
<tr>
<td>AST (IU/L)</td>
<td>24 (9–974)</td>
<td>23 (10–974)</td>
<td>24 (9–176)</td>
</tr>
<tr>
<td>Total Bilirubin (μmol/L)</td>
<td>7.8 (2.2–59.1)</td>
<td>7.7 (2.2–59.1)</td>
<td>8.3 (2.8–27.6)</td>
</tr>
<tr>
<td>Direct Bilirubin (μmol/L)</td>
<td>3.0 (0.3–40.5)</td>
<td>2.9 (0.3–40.5)</td>
<td>3.1 (1.2–11.5)</td>
</tr>
<tr>
<td>HBV load (log10 copies/mL)</td>
<td>4.4 (2.4–9.2)</td>
<td>4.4 (2.4–9.2)</td>
<td>4.7 (2.5–8.7)</td>
</tr>
</tbody>
</table>

IU: international unit; data are given as median with range; ALT: alanine aminotransferase; AST: aspartate aminotransferase. P values are presented for comparisons between HDV negativity vs. HDV positivity.

https://doi.org/10.1371/journal.pone.0175304.t002
Fig 1. Nested HDV specific RT-PCR. (a) Primers for HDV-specific nested PCRs were selected in highly conserved regions of the HDV genome. For detecting HDV RNA genomes, primers HDV57-F and HDV60-R.
The aminotransferase enzymes (ALT and AST: 43.6 IU/L and 35.0 IU/L vs. 43.5 IU/L and 36.3 IU/L, respectively; \( P > 0.05 \)) as well as total bilirubin (8.5 \( \mu \)mol/L vs. 8.7 \( \mu \)mol/L), and direct bilirubin (3.5 \( \mu \)mol/L vs. 3.4 \( \mu \)mol/L) were not significantly higher in HDV positive compared to HDV negative HBV-infected patients (\( P > 0.05 \)). The HBV-DNA loads were not significantly higher in HDV negative patients in comparison to HBV-HDV coinfected patients (5.0 log10 copies/mL vs. 5.3 log10 copies/mL; \( P = 0.42 \)).

Although HDV-1 seems to be less predominant in comparison with the HDV-2 in this study, patients with HDV-1 showed higher HBV-DNA loads as compared to those with HDV-2.

### Table 3. Distribution of HBV and HDV genotypes in HBV-HDV coinfected individuals.

<table>
<thead>
<tr>
<th>Nr.</th>
<th>Sample ID</th>
<th>Age</th>
<th>Gender</th>
<th>HBV load(^1) (copies/mL)</th>
<th>HBV genotype</th>
<th>HDV genotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>HM008</td>
<td>28</td>
<td>Female</td>
<td>8.7</td>
<td>B</td>
<td>1</td>
</tr>
<tr>
<td>2</td>
<td>HM014</td>
<td>22</td>
<td>Female</td>
<td>8.4</td>
<td>B</td>
<td>1</td>
</tr>
<tr>
<td>3</td>
<td>HM049</td>
<td>33</td>
<td>Male</td>
<td>8.4</td>
<td>C</td>
<td>1</td>
</tr>
<tr>
<td>4</td>
<td>HM052</td>
<td>41</td>
<td>Male</td>
<td>7.7</td>
<td>B</td>
<td>1</td>
</tr>
<tr>
<td>5</td>
<td>HM080</td>
<td>62</td>
<td>Female</td>
<td>3.7</td>
<td>B</td>
<td>1</td>
</tr>
<tr>
<td>6</td>
<td>HM054</td>
<td>34</td>
<td>Male</td>
<td>4.4</td>
<td>B</td>
<td>2</td>
</tr>
<tr>
<td>7</td>
<td>HM062</td>
<td>45</td>
<td>Female</td>
<td>5.7</td>
<td>B</td>
<td>2</td>
</tr>
<tr>
<td>8</td>
<td>HM067</td>
<td>45</td>
<td>Male</td>
<td>5.7</td>
<td>B</td>
<td>2</td>
</tr>
<tr>
<td>9</td>
<td>HM095</td>
<td>39</td>
<td>Male</td>
<td>3.2</td>
<td>B</td>
<td>2</td>
</tr>
<tr>
<td>10</td>
<td>HM115</td>
<td>24</td>
<td>Male</td>
<td>7.9</td>
<td>B</td>
<td>2</td>
</tr>
<tr>
<td>11</td>
<td>HM116</td>
<td>24</td>
<td>Male</td>
<td>6.2</td>
<td>C</td>
<td>2</td>
</tr>
<tr>
<td>12</td>
<td>HM121</td>
<td>32</td>
<td>Male</td>
<td>3.7</td>
<td>B</td>
<td>2</td>
</tr>
<tr>
<td>13</td>
<td>HM122</td>
<td>35</td>
<td>Male</td>
<td>6.0</td>
<td>B</td>
<td>2</td>
</tr>
<tr>
<td>14</td>
<td>HM137</td>
<td>31</td>
<td>Male</td>
<td>4.7</td>
<td>B</td>
<td>2</td>
</tr>
<tr>
<td>15</td>
<td>HM141</td>
<td>56</td>
<td>Female</td>
<td>6.0</td>
<td>B</td>
<td>2</td>
</tr>
<tr>
<td>16</td>
<td>HM146</td>
<td>38</td>
<td>Female</td>
<td>8.7</td>
<td>B</td>
<td>2</td>
</tr>
<tr>
<td>17</td>
<td>HM149</td>
<td>39</td>
<td>Male</td>
<td>4.5</td>
<td>C</td>
<td>2</td>
</tr>
<tr>
<td>18</td>
<td>HM178</td>
<td>36</td>
<td>Female</td>
<td>8.6</td>
<td>B</td>
<td>2</td>
</tr>
<tr>
<td>19</td>
<td>HM195</td>
<td>51</td>
<td>Female</td>
<td>2.9</td>
<td>B</td>
<td>2</td>
</tr>
<tr>
<td>20</td>
<td>HM223</td>
<td>26</td>
<td>Female</td>
<td>2.8</td>
<td>B</td>
<td>2</td>
</tr>
<tr>
<td>21</td>
<td>HM224</td>
<td>32</td>
<td>Male</td>
<td>2.6</td>
<td>B</td>
<td>2</td>
</tr>
<tr>
<td>22</td>
<td>HM232</td>
<td>59</td>
<td>Female</td>
<td>3.7</td>
<td>B</td>
<td>2</td>
</tr>
<tr>
<td>23</td>
<td>HM233</td>
<td>48</td>
<td>Male</td>
<td>2.7</td>
<td>B</td>
<td>2</td>
</tr>
<tr>
<td>24</td>
<td>HM239</td>
<td>50</td>
<td>Male</td>
<td>2.5</td>
<td>B</td>
<td>2</td>
</tr>
<tr>
<td>25</td>
<td>HM240</td>
<td>43</td>
<td>Male</td>
<td>2.8</td>
<td>B</td>
<td>2</td>
</tr>
</tbody>
</table>

\(^1\) Values are given as log\(_{10}\) copies/mL.

https://doi.org/10.1371/journal.pone.0175304.t003
Fig 2. Phylogenetic analyses of HBV genomes in South Central Vietnamese HBsAg-positive patients. Phylogenetic tree was inferred from distance analysis (Kimura 2 parameters model) and neighbor-joining reconstruction from S gene region of HBV sequence (nt 455–786, numbering is referred to HM011485). South Central Vietnamese HBV sequences are referred to as “letter/number”, i.e., “HM115”. The South Central Vietnamese HBV sequences were compared to HBV reference sequences, gathering the seven HBV genotypes (GenBank accession numbers are denoted in the figure). Phylogenetic analysis of HBV region nt455 to nt 786 showed that the HDV sequences were clustered in the Asian HBV-genotype branches 1 and 4.

https://doi.org/10.1371/journal.pone.0175304.g002
Distribution of HDV genotypes

The sequences of the 25 HDV-RNA-positive samples that amplified HDAg are illustrated in Fig 4A. Patient-specific HDV isolates were confirmed by sequence variations of the analysed HDAg gene region (Fig 4B; all sequences were submitted to the GenBank Database and the Accession number allotted from KX897956 to KX897980). Phylogenetic analysis was performed using sequences of the HDV amplicons and analysis showed that all analyzed HDV genotypes belong to either HDV-1 or HDV-2. The HDV strains also clustered in the Asian clade. Notably, 20/25 (80%) HDV isolates fit into the clade of genotype 2 (Fig 4B).

Discussion

Nearly 40 years after discovery of HDV, the disease caused by this virus yet remains a major problem in regions where HBV is endemic. There are so far no recommended standard therapy and diagnosis in place for HDV treatment in Vietnam. The incidence of HDV and its interaction with HBV carriers is sparsely reported in Central Vietnam, a HBV endemic region. HDV incidences and prevalences are under reported in several Asian countries where HBV is endemic and the significance of HDV infection is poorly studied in Vietnam. This very first study provides epidemiological data on HDV infection in Central Vietnam, with a higher representation of HDV-2 among chronic HBV patients.

In European countries, HDV prevalence has diminished because of available HBV antiviral therapies and due to the successful implementation of HBV vaccination regimen [39]. However, recently, an increasing number of reports claim that HDV incidence is at rise because of increased influx of immigrants from HBV and HDV endemic areas [6, 40] and, therefore, an increased HDV seroprevalence exist (8–20%) [6, 41, 42]. In Asia, the HDV infection have been reported in Mongolia (56.5%), Pakistan (≥60%), India (37%), and China (15%) [28, 43–45]. However in other Asian countries such as Korea (0.32%), Indonesia (<0.5%), and Philippines (1.6%), a low HDV prevalence is reported [43, 46, 47].

The hepatitis delta virus distribution varies across different geographical regions and even within a country [6, 14]. For example, the prevalence of HDV infection in HBsAg-positive individuals varied between Western and South Eastern regions of Turkey (5% vs. 27%) [48]. Such intra-regional distributions are likely within a country. In the presented study, we
Fig 4. Phylogenetic analyses of HDV genomes in chronic HBsAg-positive patients in South Central Vietnam. (a) Representative HDV sequences of South Central Vietnamese HBV-HDV infection patients showing patient-specific HDV isolates. (b) Phylogenetic tree was inferred from distance analysis (Kimura 2 parameters model) and neighbor-joining reconstruction from HDV-region sequences. South Central Vietnamese HDV sequences are referred to as “letter/number”, i.e., “HM115”. The South Central Vietnamese HDV sequences were compared to HDV reference sequences, gathering the eight HDV clades (GenBank accession numbers are denoted in the figure). Phylogenetic analysis of HDV region nt 888 to nt 1122 showed that the HDV sequences were clustered in the Asian HDV-branches 1 and 5.

https://doi.org/10.1371/journal.pone.0175304.g004
observed that HDV-RNA prevalence is 10% in HBsAg-positive patients compared to a previous study that reported 15% HDV-RNA positive cases among HBsAg carriers in Northern Vietnam [31]. This difference might be due to the region-related burden of the disease or may likely result from the different cohorts of these two studies. In a previous study, hospitalized patients with severe and advanced liver diseases including acute hepatitis, active chronic hepatitis, liver cirrhosis and liver cancer were selected. In this study, we selected HBsAg-positive patients presenting mild hepatitis. HDV was determined as a culprit for more severe hepatitis than HBV monoinfection which can accelerate the progression of chronic hepatitis B to cirrhosis and HCC [49, 50].

Thus far, eight major HDV clades have been identified and distributed over different geographic areas [8]. Overall, HDV-1 is the most common, which is distributed worldwide and has a broad spectrum of pathogenicity [8, 51], whereas HDV-2 to 8 seem to occur more regionally; however, HDV-2 is mainly found in East Asia such as Japan [8, 20]. Although HDV-1 and -2 circulate in Northern Vietnam as reported earlier, HDV-1 represents a major genotype (HDV-1: 91% vs. HDV-2: 9%) [31]. Surprisingly, the results of this current study showed a contradictory pattern of molecular epidemiology with predominance of HDV-2 compared to HDV-1 (HDV-2: 80% vs. HDV-1: 20%). Therefore, we speculate that the distribution of HDV genotypes might differ from region to region as seen in Central Vietnam and Northern Vietnam. However, further studies with a larger sample size are needed to confirm this differential distribution of HDV genotypes across regions within Vietnam.

Several studies have concluded that chronic hepatitis D can exacerbate the pre-existing liver damage leading to a rapid progression to liver cirrhosis and liver cancer compared to chronic hepatitis B monoinfection or chronic hepatitis C [1, 3, 4]. Heidrich et al has demonstrated that, in the clinical course of HBV-HDV coinfection, HBV-DNA levels are frequently low, suggesting inhibitory effects of HDV on HBV regardless of the phase of HBV infection [52]. In addition, among many viral and host factors, HDV genotypes may also contribute to the clinical course and influences the liver disease outcomes. HDV-1 is associated with both severe and mild course, while HDV-2 induces a mild course [14]. Another study investigated the impact of HDV-1 and -2 on clinical implications in HBV-infected patients. The results showed that patients infected with HDV-2 had significantly lower ALT levels and a trend to have lower serum HDV-RNA levels as compared with those infected with HDV-1 [51]. In line with mentioned studies, we showed that the levels of HBV-DNA were higher in HDV-1 patients than in HDV-2 patients. This finding could not reflect fully the clinical significance of HDV towards the clinical outcome of HBV-HDV coinfection due to a relatively small number of HDV positive patients in this cohort. HDV-1 patients were younger than HDV-2 patients in the analyzed patient cohort. Therefore it could not be excluded that the difference in viral loads could be also due to, e.g., an age effect and should be investigated in larger studies.

Although, our current study has characterized the molecular epidemiology of HDV in Central Vietnam, our study has limitations. Firstly, this study is designed as a cross-sectional study and therefore we could not follow up the positive HDV patients over the course of HBV-HDV coinfection. Secondly, we could not assess in detail the influences of HDV infection on the clinical significance and the severity of liver diseases in HBV-HDV coinfection. This might be due to the small sample size and the absence of severe forms of liver diseases, including liver cirrhosis and hepatocellular carcinoma, of the HBsAg-positive outpatients. Importantly, liver biopsies are not available in order to measure the accumulation of the intrahepatic replication intermediates of HBV and HDV.

Our study explored the molecular epidemiology of HDV in Central Vietnam which is to the best of our knowledge the first report with respect to this highly HBV endemic region of Vietnam. Our findings indicate that HDV infection is highly prevalent in which HDV-2 is
predominant in Central Vietnam. This study provides new insights into the prevalence and genotype distribution as well as risk of HDV infection in Central Vietnam. However, further studies need to be conducted to understand the molecular epidemiology of HDV in different regions in Vietnam.

Author Contributions

Conceptualization: HMN BTS TPV CTB.
Formal analysis: HMN BTS NXH.
Funding acquisition: HMN.
Investigation: HMN BTS NXH.
Methodology: HMN BTS CTB.
Project administration: HMN CTB.
Resources: HMN BTS.
Supervision: HMN CTB.
Validation: HMN BTS NXH CTB.
Visualization: HMN BTS NXH CTB.
Writing – original draft: HMN BTS NXH NTT CTB.
Writing – review & editing: HMN BTS NXH NTT HW TPV CTB.

References


